Pfizer is in the midst of seeking its US authorization for its third vaccine for COVID-19. It claimed on Thursday that another shot within 12 months will augment immunity and keep at bay the latest mutants arising.
According to certain research in several countries, Pfizer amongst the many other utilized vaccines offers a high level of immunity against the delta variant. This new variant has posed a cause of concern for a large number of cases not only in the USA but also around the world. In cases of the majority of the vaccines, two jabs become integral to develop antibodies. Whilst some countries have been undertaking their vaccine campaigns on a war footing, some are still fumbling to get their hands on the doses.
Since the virus is novel, continuous research becomes integral and thus new developments are constantly emerging. Some study claims that since antibodies dwindle over time, boosters may be needed. Sources say that the company plans to ask Food and Drug Administration for emergency approval for the third dose. But the battle doesn’t end there, public health authorities will then concur if the said third vaccine is really needed.
Dr Mikael Dolsten of Pfizer in conversation with The Associated Press suggested that initial data from the study shows an individual’s antibody level jumps up to 5-10 times post the third jab when compared to the earlier taken second dose.
Share
Tweet
